Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
12
KZIA Quote, Financials, Valuation and Earnings
Last price:
$3.01
Seasonality move
:
9.64%
Day range:
$2.91 - $3.00
52-week range:
$1.87 - $15.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.76x
Volume:
16.6K
Avg. volume:
75.4K
1-year change:
-28.89%
Market cap:
$12.7M
Revenue:
$1.5M
EPS (TTM):
-$6.67
Analysts' Opinion
-
Consensus RatingKazia Therapeutics has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Kazia Therapeutics has an estimated upside of 586.69% from its current price of $2.91.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.91.
Fair Value
-
According to the consensus of 0 analysts, Kazia Therapeutics has 586.69% upside to fair value with a price target of -- per share.
KZIA vs. S&P 500
-
Over the past 5 trading days, Kazia Therapeutics has underperformed the S&P 500 by -16.86% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Kazia Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kazia Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Kazia Therapeutics reported revenues of --.
Earnings Growth
-
Kazia Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Kazia Therapeutics reported earnings per share of --.
Enterprise value:
12M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.91x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-106.28%
Net Income Margin (TTM):
--
Return On Equity:
-1083.16%
Return On Invested Capital:
-784.09%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2006-06-30 | 2007-06-30 | 2008-06-30 | 2007-06-30 | 2008-06-30 | |
| Income Statement | ||||||
| Revenue | $13.1M | $13.5M | $11.9M | $2.8M | $2.7M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -$34M | -$34.2M | |
| EBITDA | -- | -- | -- | -$34M | -$34.2M | |
| Diluted EPS | -- | -- | -- | -$40.30 | -$43.33 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.3M | -- | -- | $7.1M | $4.1M | |
| Total Assets | $15.8M | -- | -- | $18.6M | $14.4M | |
| Current Liabilities | $3.5M | -- | -- | $5M | $17.2M | |
| Total Liabilities | $6.1M | -- | -- | $10.6M | $21.1M | |
| Total Equity | $9.7M | -- | -- | $8M | -$6.7M | |
| Total Debt | -- | -- | -- | $1.2M | $423.8K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 | 2021-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$3.5M | -- | -- | -$9M | -$8.3M | |
| Cash From Investing | $1.7M | -- | -- | -- | $9.4K | |
| Cash From Financing | $2.6M | -- | -- | $17.3M | $12.2K | |
| Free Cash Flow | -$3.5M | -- | -- | -- | -- | |
KZIA
Sector
Market Cap
$12.7M
$46.1M
Price % of 52-Week High
18.42%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-48.1%
-0.6%
1-Year Price Total Return
-28.89%
-30.52%
Beta (5-Year)
1.977
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$3.13
200-day SMA
Sell
Level
$3.80
Bollinger Bands (100)
Sell
Level
3.36 - 5.28
Chaikin Money Flow
Sell
Level
-19.2M
20-day SMA
Sell
Level
$3.96
Relative Strength Index (RSI14)
Sell
Level
29.80
ADX Line
Sell
Level
7.14
Williams %R
Buy
Level
-93.299
50-day SMA
Sell
Level
$4.85
MACD (12, 26)
Sell
Level
-0.60
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
70.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-12.5327)
Sell
CA Score
(Annual)
Level (-7.6736)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (13.6637)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
Stock Forecast FAQ
In the current month, KZIA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KZIA average analyst price target in the past 3 months is --.
-
Where Will Kazia Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kazia Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Kazia Therapeutics?
Analysts are divided on their view about Kazia Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kazia Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Kazia Therapeutics's Price Target?
The price target for Kazia Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KZIA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kazia Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of KZIA?
You can purchase shares of Kazia Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kazia Therapeutics shares.
-
What Is The Kazia Therapeutics Share Price Today?
Kazia Therapeutics was last trading at $3.01 per share. This represents the most recent stock quote for Kazia Therapeutics. Yesterday, Kazia Therapeutics closed at $2.91 per share.
-
How To Buy Kazia Therapeutics Stock Online?
In order to purchase Kazia Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 2.02% over the past day.
